Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Mar 07 2022

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 4 pages · English

Summary by 6ix AI

Oxemia is an oral tablet that serves as an alternative to injectable treatments and has received approval from the Drug Controller General of India. The drug has shown positive results in clinical trials, improving hemoglobin levels and offering a safer treatment option for patients. This development marks a significant milestone for Zydus in its innovation journey within the nephrology segment.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Cadila Healthcare Limited has informed the Exchange about press release dated 07-Mar-2022 titled Zydus to launch Oxemia (Desidustat) a breakthrough treatment for Anemia in patients suffering from Chronic Kidney Disease (CKD)

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases